SecBot SecBot
8-K ·Filed Apr 27, 2026

FULC

Fulcrum Therapeutics, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-178806
8-K material event: Items 1.02
Actionable Insight ◆ Mixed

Monitor upcoming FDA feedback on trial design and the search for a new CFO, as leadership transition could impact execution despite promising clinical data.

DirectionMixed
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Fulcrum Therapeutics terminated a license agreement for its Diamond-Blackfan anemia program, reported Q1 2026 earnings with a net loss per share of $-0.25 (in line with expectations), and announced the retirement of its CFO while appointing a new board member. Despite positive clinical data for its sickle cell disease drug pociredir and a cash runway into 2029, the termination of a development program and CFO retirement create mixed sentiment.

Key Financial Metrics

EPS
−$0.25
est −$0.30 · +16.7%
Revenue
$0.00
est $0.00
Rating
in line

Key Facts

  • Terminated license agreement for Diamond-Blackfan anemia program with CAMP4 Therapeutics
  • Net loss per share of $-0.25 for Q1 2026, in line with consensus estimate of $-0.30
  • Cash position decreased to $333.3 million from $352.3 million in Q4 2025
  • CFO Alan Musso plans to retire later this year
  • Appointed Josh Lehrer, M.D., to the Board of Directors

Financial Impact

Net loss of $18.9 million for Q1 2026, cash runway into 2029

epscashr&d_expenses

Risk Factors

  • Termination of Diamond-Blackfan anemia program eliminates potential future revenue stream
  • CFO retirement creates leadership uncertainty during a critical development phase

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-178806
Document: fulc-20260423.htm0001193125-26-178806
Document: 0001193125-26-178806-index-headers.html0001193125-26-178806
Document: 0001193125-26-178806-index.html0001193125-26-178806
Document: 0001193125-26-178806.txt0001193125-26-178806
8-K Data (Synthetic)0001193125-26-178806

Track record

23 reports on FULC

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  5. Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  6. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  7. Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
  8. Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
  9. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
  10. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026